Trials / NCT02720640
Safety and Efficacy of the Alpha AMS Subretinal Implant
Completed N/A Gene therapy, Retinal implant
- Sponsor
- University of Oxford
- Treatment
- Implant 'on' vs implant 'off'
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Started
- 2015-05
- Main results expected
- 2017-10
- Results posted
- Not yet
- Record last updated
- 2017-11-17
What the study is testing
The aim of this single-centre study is to assess the safety and efficacy of the Retina Implant Alpha AMS (Retina Implant AG, Reutlingen, Germany) in participants with severe visual impairment secondary to outer retinal degeneration caused by retinitis pigmentosa (RP). The study is sponsored by the University of Oxford and funded by the National Institute for Health Research (UK).
Where it runs
United Kingdom (1)
- Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire